Inactive Instrument

Highlights Applied Molecular Transport Inc.

Equities

AMTI

US03824M1099

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Cyclo Therapeutics, Applied Molecular Transport Complete Merger	12-27	MT
Cyclo Therapeutics, Inc. completed the acquisition of Applied Molecular Transport Inc. from a group of shareholders for $10.2 million.	12-26	CI
Applied Molecular Transport Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Cyclo Therapeutics, Applied Molecular Transport Agree to Merge	21/09/23	MT
Applied Molecular Transport Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Applied Molecular Transport Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
APPLIED MOLECULAR TRANSPORT INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	09/03/23	AQ
Applied Molecular Transport Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	09/03/23	CI
Applied Molecular Transport Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	09/03/23	CI
Applied Molecular Transport Inc. Presents Additional Data from Oral AMT-101 Phase 2 FILLMORE Trial in Chronic Pouchitis at ECCO'23 Congress	03/03/23	CI
Applied Molecular Transport Inc. Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis	22/12/22	CI
Applied Molecular Transport's AMT-101 Gets FDA Orphan Drug Designation for Pouchitis Treatment; Shares up	10/11/22	MT
APPLIED MOLECULAR TRANSPORT INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	07/11/22	AQ
Applied Molecular Transport Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	07/11/22	CI
Applied Molecular Transport Completes Enrollment of Phase 2 Lombard Monotherapy Trial of Oral Amt-101 in Patients with Moderate-To-Severe Ulcerative Colitis	20/09/22	CI
APPLIED MOLECULAR TRANSPORT INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	04/08/22	AQ
Applied Molecular Transport Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	04/08/22	CI
Applied Molecular Transport Announces Top-Line Phase 2 Results from Market Combination Trial of Oral AMT-101 in Patients with Moderate-To-Severe Ulcerative Colitis	06/07/22	CI
APPLIED MOLECULAR TRANSPORT INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	09/05/22	AQ
Applied Molecular Transport Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	09/05/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Applied Molecular Transport Inc.

Equities

AMTI

US03824M1099

Highlights

Filters